Eblasakimab is a Monoclonal Antibody owned by Aslan Pharmaceuticals, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.

ASLAN-004 is a fully human monoclonal antibody acting against interleukin-13 receptor alpha and IL4. The drug candidate block the binding and signal transduction of both IL4 and IL13. By targeting IL-13,it blocks type 2 receptor comlex. This results in the inhibition of JAK1, STAT3 and STAT6 pathway. The drug candidate results in the inhibition of bronchoconstriction and other asthma related allergic reactions and also causes inhibition of IL-13 signalling which acts as an immune checkpoint for tumour evasion and enhances the immune infiltrate in the tumour microenvironment.

The revenue for Eblasakimab is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eblasakimab NPV Report.

Eblasakimab was originated by CSL and is currently owned by Aslan Pharmaceuticals.

Eblasakimab Overview

eblasakimab (ASLAN-004) is under development for the treatment of allergic disease such as  asthma, unspecified type-2 driven disease and atopic eczema. It is administered through intravenous and subcutaneous route. The drug candidate is a monoclonal antibody act against interleukin-13 receptor alpha 1 and IL-4. It was under development for the treatment of solid tumors.

Aslan Pharmaceuticals Overview

Aslan Pharmaceuticals is a clinical-stage biotechnology company that develops novel therapeutics for various oncology diseases. The company’s pipeline products include Varlitinib, ASLAN003, ASLAN004 and ASLAN002. Its Varlitinib is a pan-HER inhibitor used for the treatment of biliary tract cancer, gastric cancer, breast cancer and colorectal cancer. Aslan Pharmaceuticals’ ASLAN003 is a DHODH inhibitor used for the treatment of acute myeloid leukemia; ASLAN004 is an IL-4/IL-13 receptor inhibitor used for the treatment of asthma and atopic dermatitis; and ASLAN002 is a RON/MET inhibitor used for the treatment of solid tumors. The company conducts regional clinical development programs across Asia. It operates its offices in Singapore, Taiwan and China. Aslan Pharmaceuticals is headquartered in Singapore.

The operating loss of the company was US$31.5 million in FY2021, compared to an operating loss of US$16.4 million in FY2020. The net loss of the company was US$31.3 million in FY2021, compared to a net loss of US$16.2 million in FY2020.

Quick View – Eblasakimab

Report Segments
  • Innovator
Drug Name
  • Eblasakimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Oncology
  • Respiratory
  • Undisclosed
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.